Abstract: A light source apparatus is provided with the emission section in which a plurality of vertical-cavity surface-emitting laser light-emitting elements is arrayed, the driving circuit section that causes the plurality of light-emitting elements of the emission section to emit light, the temperature detection section that includes a plurality of temperature sensors arranged to detect the temperature of the emission section, and a control section. The control section is configured to, during an emission target period when the light-emitting elements of the emission section are driven by the driving circuit section, correct a detection value from each of the plurality of temperature sensors by using a correction value set for each of the temperature sensors.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: Provided is a method of manufacturing a crystallized stacked structural body excellent in manufacturing efficiency. The present invention is characterized by including: a stacked structural body forming step of forming a stacked structural body (7) in which an Sb2Te3 layer (5) having a thickness of from 2 nm to 10 nm and a GeTe layer (6) having a thickness of more than 0 nm and 4 nm or less are stacked, and a trace addition element (S or Se) is incorporated at a content of from 0.05 at % to 10.0 at % into the GeTe layer (6) on an orientation control layer (4) configured to give, to the Sb2Te3 layer (5) and the GeTe layer (6) at the time of their crystallization, a common crystal axis, the step being performed under a temperature of less than 100° C. including room temperature; an Sb2Te3 layer-crystallizing step of crystallizing the Sb2Te3 layer (5) by heating and holding the stacked structural body (7) at a first crystallization temperature of 100° C. or more and less than 170° C.

Abstract: An operation log acquisition device includes processing circuitry configured to store a determination image that is an image of a characteristic area of an operation screen that is used to perform a predetermined operation, an event occurrence area in which an event may occur when the predetermined operation is performed, operation type specifying information that specifies an operation type, and an acquisition image area that is to be acquired when the predetermined operation is performed, in association with each other, upon detecting an occurrence of the event, acquire an occurrence time of the event, an occurrence position of the event, and a captured image of the operation screen, and determine whether or not the captured image acquired includes a matching area that the determination image matches, and acquire an event occurrence area of the determination image if the captured image includes the matching area.

Abstract: A lighting device includes a substrate, a first conductive portion, a second conductive portion disposed with a spacing as to the first conductive portion, a first reflective layer having a first opening coinciding with the first conductive portion and a second opening coinciding with the second conductive portion, a light-emitting part connected to the first conductive portion through the first opening, a non-light-emitting part connected to the second conductive portion through the second opening, and a second reflective layer. The second reflective layer includes a first reflective portion disposed around the light-emitting part, and a second reflective portion disposed around the non-light-emitting part.

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: A management device obtains a first operational process, which is an operational process described in an operational procedure manual for an application, and a second operational process, which is an operational process performed by a user on the application. The management device further determines whether the first operational process is consistent with the second operational process or not. If the management device determines that the first operational process is not consistent with the second operational process, the management device displays a review screen to check inconsistency between the operational processes.

Abstract: A lighting device includes a substrate, a first conductive portion, a second conductive portion disposed with a spacing as to the first conductive portion, a first reflective layer having a first opening coinciding with the first conductive portion and a second opening coinciding with the second conductive portion, a light-emitting part connected to the first conductive portion through the first opening, a non-light-emitting part connected to the second conductive portion through the second opening, and a second reflective layer. The second reflective layer includes a first reflective portion disposed around the light-emitting part, and a second reflective portion disposed around the non-light-emitting part.

Abstract: A debug information abstraction unit (32) of a proxy server (30) adds, when a predetermined rule of an extension program is embodied into a program, a program for outputting debug information regarding the predetermined rule to the embodied program. Then, a debug information transmission unit (41b) of a terminal device (40) transmits, to a debug support device (10), the debug information regarding the predetermined rule for which the program has been added.

Abstract: An illumination device includes a plurality of light sources, each having a light-emission surface that faces a side opposite to a display panel; a light-source substrate that has a mount surface on a side opposite to the display panel, and that has light transmissivity, the mount surface being provided for mounting the plurality of light sources thereon; and a reflecting layer that is provided on a side of the light-source substrate opposite to the display panel so as to be spaced from the light-emission surfaces by a predetermined interval, and that reflects toward the light-source substrate light coming from the light sources, wherein the illumination device illuminates the display panel with light.

Abstract: A lighting device includes a plurality of light sources arranged side by side in a plane and a wavelength conversion sheet arranged to face a light emitting surface of each of the light sources and converting a wavelength of light from the light sources, in which the wavelength conversion sheet includes a base material having transparency, and a wavelength conversion layer in which a plurality of protrusions containing a wavelength conversion material and having a spherical surface are arranged side by side without gaps on a principal surface of the base material opposite to the light sources.

Abstract: An illumination device includes a light source, a first optical member, and a fixing portion. The first optical member includes a light reflection portion configured to reflect light, at least a part of the light reflection portion overlapping with the light source, and a light transmitting portion configured to transmit light, the light transmitting portion not overlapping the light reflection portion. A center of the light source in a plan view is defined as a first center, and a center of the light reflection portion in a plan view is defined as a second center. In the light reflection portion, the second center is located between the fixing portion and the first center at a first temperature, and at a second temperature higher than the first temperature, a position of the second center is closer to the first center than a position of the second center at the first temperature.

Abstract: An illumination device includes a light source, a first optical member, and a fixing portion. The first optical member includes a light reflection portion configured to reflect light, at least a part of the light reflection portion overlapping with the light source, and a light transmitting portion configured to transmit light, the light transmitting portion not overlapping the light reflection portion. A center of the light source in a plan view is defined as a first center, and a center of the light reflection portion in a plan view is defined as a second center. In the light reflection portion, the second center is located between the fixing portion and the first center at a first temperature, and at a second temperature higher than the first temperature, a position of the second center is closer to the first center than a position of the second center at the first temperature.

Abstract: A display control device has display setting information including setting information of a layer structure of display objects on a terminal screen and setting information of a group to which the display objects belong, display state information indicating a display state of the display object, and operation setting information defining which setting content a combination of an operation target and operation content on a screen indicate for a layer structure and a group of display objects for each combination of the operation target and the operation content. The display control device specifies the setting content to the display object based on the combination of the operation target and the operation content, the display state information, and the operation setting information when an operation on the display object occurs.

Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: [PROBLEM] An object of the present invention is to provide a nonvolatile memory device having an excellent information retention characteristic, exhibiting high performance, and achieving practical mass-production, and a manufacturing method therefor. [SOLUTION] A nonvolatile memory device 1 has a laminated structure part including a plurality of Al2O3 layers 4 and a plurality of SiO2 layers 6 formed as two types of insulating layers formed with different compositions and disposed alternately, and an O-M1-O layer 5 of a 0.5 molecular layer to a 2.0 molecular layer, formed by a chemical bond between a metal element M1 and oxygen, and disposed on each joining interface between the insulating layers, the metal element M1 being an element other than elements constituting the insulating layers, and the nonvolatile memory device stores information by modulating an interface dipole induced in the vicinity of the O-M1-O layer 5 by external electrical stimulation.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La—(CH2)n2—C(?O)—wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.

Abstract: An acquisition unit acquires image data by performing screen capture of a screen operated by a user, at a predetermined interval. A detection unit detects the user operation. An estimation unit estimates an amount of delay time from a user operation time point to a time point at which the user operation is detected by the detection unit. The selection unit selects image data of the user operation time point out of the acquired image data.

Abstract: A peripheral information acquisition unit (121) acquires information relating to a first application (13a) running in a terminal, information relating to control of the terminal, or information that can be acquired from a sensor included in the terminal, as peripheral information. The peripheral information acquired by the peripheral information acquisition unit (121) is accumulated in a peripheral information accumulation unit (122). A dialogue interface unit (11) accepts input of information from a user and outputs information to the user. When the peripheral information accumulated in the peripheral information accumulation unit (122) and information input to the dialogue interface unit (11) satisfy a predetermined condition, a scenario control unit (123) causes the dialogue interface unit (11) to output information relating to execution of a second application (14) that is associated with the condition in advance.